BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company is headquartered in Carson City, Nevada.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.97M |
| Operating Margin | 0.00% |
| Return on Equity | -80.70% |
| Return on Assets | -47.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.56 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $7.50M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |